Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2019-02-19 Major Shareholding Noti…
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 1 TO SCHEDULE 13G
Major Shareholding Notification
2019-02-19 English
SCHEDULE 13G
Major Shareholding Notification
2019-02-19 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release about a presentation at a healthcare conference. The document length is 2032 characters, which is relatively short and mainly serves as an announcement rather than a full report. There are no financial statements or detailed financial data included. The document is not an annual report, earnings release, or detailed investor presentation but rather a regulatory filing to disclose a press release. Therefore, it fits best under Regulatory Filings (RNS).
2019-02-19 English
FEBRUARY 14, 2019
Major Shareholding Notification
2019-02-14 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a press release announcement about a patent and does not include financial statements or detailed financial data. The document length is short (2041 characters) and it primarily serves as a regulatory announcement rather than a full report. According to the rules, Form 6-K filings are typically regulatory filings for foreign issuers to report material information between annual reports. Therefore, this document fits best under Regulatory Filings (RNS).
2019-01-17 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release announcing the closing of a $20 million underwritten offering. The content focuses on a financing event rather than a full financial report or other types of filings. The document length is short (2047 characters), and it is primarily an announcement of a capital raising event. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-12-11 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.